Mark Manfredi brings over two decades of international biopharmaceutical industry leadership and cancer drug discovery success to DISCOFinancing ...
A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may ...
Using BostonGene's multi-parameter immune phenotyping platform and immunotype signature scores, clinicians at MD Anderson profiled peripheral blood from patients with triple-negative breast cancer ...
New approaches hurdle biological barriers to attack recalcitrant targets to tackle difficult-to-treat and recurrent cancers.
Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company ...
SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the Oppenheimer Movers in Rare Disease Summit being ...
Insilico Medicine, Mabwell Bioscience and ChemExpress have entered a strategic partnership to create a novel antibody–drug ...
OncoPrecision Corporation ("OncoPrecision"), a translational therapeutics company developing novel antibody-based cancer ...
As bispecifics, ADCs, protein degraders, and AI-designed mini-proteins move into the clinic, discovery teams face a new ...
The Republic may not have a major player to call its own, but licensing deals and early-stage breakthroughs can still count ...
A team of researchers at IOCB Prague headed by Dr. Tomáš Slanina has developed a new method for labeling molecules with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback